Table 4.
PLGA-based NPs that have undergone clinical trials in the last decade.
| Name/Company | Surface Functionality | Drug | Investigated Application | ClinicalTrials.gov Identifier Number/Status |
|---|---|---|---|---|
| BIND-014/BIND Therapeutics | PEG | Docetaxel | Advanced urothelial carcinoma, cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree and squamous cell carcinoma of the head and neck | NCT02479178/Phase II completed (January 2020) |
| v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation positive or squamous cell non-small cell lung cancer (NSCLC) that have progressed after treatment of one prior platinum-containing chemotherapy regimen | NCT02283320/Phase II completed (April 2016) | |||
| Metastatic castration-resistant prostate cancer | NCT01812746/Phase II completed (April 2016) | |||
| Advanced NSCLC | NCT01792479/Phase II completed (April 2016) | |||
| Advanced or metastatic cancer | NCT01300533/Phase I completed (February 2016) | |||
| RECIOUS-01/Radboud University | – | IMM60 and NY-ESO-1 | Advanced solid tumor (immunomodulatory) | NCT04751786/Phase I recruiting (Estimated study completion date: December 2022) |